Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,581 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $38.92, for a total value of $450,732.52. Following the sale, the chief financial officer now owns 112,933 shares of the company’s stock, valued at approximately $4,395,352.36. This trade represents a 9.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.44, for a total value of $283,039.64.
• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Trading Up 0.6 %

Shares of Hims & Hers Health stock opened at $42.12 on Thursday. The firm has a market cap of $9.20 billion, a PE ratio of 95.72 and a beta of 1.35. The stock has a 50 day moving average of $29.82 and a 200 day moving average of $23.00. Hims & Hers Health, Inc. has a 12 month low of $8.58 and a 12 month high of $44.43.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the firm posted ($0.04) earnings per share. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HIMS shares. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Piper Sandler increased their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday, January 6th. Finally, TD Cowen restated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $25.13.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. raised its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock worth $47,000 after purchasing an additional 1,508 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter worth approximately $48,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.